Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.

Ready NE, Lipton A, Zhu Y, Statkevich P, Frank E, Curtis D, Bukowski RM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):576-83.

2.

A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.

Gore L, Holden SN, Cohen RB, Morrow M, Pierson AS, O'Bryant CL, Persky M, Gustafson D, Mikule C, Zhang S, Palmer PA, Eckhardt SG.

Ann Oncol. 2006 Nov;17(11):1709-17. Epub 2006 Sep 15.

3.

A phase II study of gemcitabine plus cisplatin in previously untreated advanced ovarian cancer.

Gallardo D, Calderillo G, Serrano A, Alexander F, Rodríguez G, Pérez L, de la Garza J, Orate-Ocaña L, Otero J.

Anticancer Res. 2006 Jul-Aug;26(4B):3137-41.

4.

Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer.

Seo JH, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Kim AR, Lee JB, Koo BH.

Cancer Chemother Pharmacol. 2007 Feb;59(2):269-74. Epub 2006 Jun 9.

PMID:
16763791
5.

Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.

Fuentes H, Calderillo G, Alexander F, Ramirez M, Avila E, Perez L, Aguirre G, Oñate-Ocaña LF, Gallardo D, Otero J.

Anticancer Drugs. 2006 Jun;17(5):565-70.

PMID:
16702814
6.

Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.

Adamo V, Magno C, Spitaleri G, Garipoli C, Maisano C, Alafaci E, Adamo B, Rossello R, Scandurra G, Scimone A.

Oncology. 2005;69(5):391-8. Epub 2005 Nov 24.

PMID:
16319510
7.

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.

Gu WZ, Joseph I, Wang YC, Frost D, Sullivan GM, Wang L, Lin NH, Cohen J, Stoll VS, Jakob CG, Muchmore SW, Harlan JE, Holzman T, Walten KA, Ladror US, Anderson MG, Kroeger P, Rodriguez LE, Jarvis KP, Ferguson D, Marsh K, Ng S, Rosenberg SH, Sham HL, Zhang H.

Anticancer Drugs. 2005 Nov;16(10):1059-69.

PMID:
16222147
8.

Update on chemotherapy for advanced bladder cancer.

Rosenberg JE, Carroll PR, Small EJ.

J Urol. 2005 Jul;174(1):14-20. Review.

PMID:
15947569
9.

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.

Theodore C, Geoffrois L, Vermorken JB, Caponigro F, Fiedler W, Chollet P, Ravaud A, Peters GJ, de Balincourt C, Lacombe D, Fumoleau P.

Eur J Cancer. 2005 May;41(8):1150-7.

PMID:
15911238
10.

A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.

Gupta SK, John S, Naik R, Arora R, Selvamani B, Fuloria J, Ganesh N, Awasthy BS.

Gynecol Oncol. 2005 Jul;98(1):134-40.

PMID:
15894360
12.

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, Fitzgerald P, Aristides M, Schiller JH.

Lung Cancer. 2005 Jan;47(1):69-80.

PMID:
15603856
13.

New targets for therapy in breast cancer: farnesyltransferase inhibitors.

Head J, Johnston SR.

Breast Cancer Res. 2004;6(6):262-8. Epub 2004 Oct 6. Review.

14.

In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.

Loprevite M, Favoni RE, De Cupis A, Scolaro T, Semino C, Mazzanti P, Ardizzoni A.

Oncol Rep. 2004 Feb;11(2):407-14.

PMID:
14719076
15.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH.

Clin Cancer Res. 2003 Jul;9(7):2520-6.

16.

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A.

J Clin Oncol. 2003 Jul 1;21(13):2492-9.

PMID:
12829668
17.
18.

Role of gemcitabine in the treatment of advanced and metastatic breast cancer.

Heinemann V.

Oncology. 2003;64(3):191-206. Review.

PMID:
12697958
20.

Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.

Nagourney RA, Brewer CA, Radecki S, Kidder WA, Sommers BL, Evans SS, Minor DR, DiSaia PJ.

Gynecol Oncol. 2003 Jan;88(1):35-9.

PMID:
12504624
Items per page

Supplemental Content

Write to the Help Desk